- Company
- Generic share in the Tamsulosin market has surpassed 60%
- by Kim, Jin-Gu Aug 5, 2021 08:46pm
- In the Tamsulosin prostate hypertrophy treatment market worth &8361;170 billion per year, Rx amount of generics increased by 10% compared to last year. During the same period, the original decreased by 10%, with generic accounting for more than 60% of the total market. According to UBIST, a pharmaceutical market research institute on the
- Company
- Keytruda's sales in Q1 of the year are ₩9 trillion
- by Aug 5, 2021 08:46pm
- MSD's Keytruda (Pembrolizumab)'s global quarterly sales surpassed $4 billion for the first time, ranking first in immuno-cancer drugs. According to related industries on the 2nd, the total global performance of five Checkpoint inhibitors (Keytruda, Opdivo, Tecentriq, Imfinzi, and Yervoy) in the first half of this year was $15.558 billion,
- Company
- Sales of PPI antiulcer agents rise 30% in 2 years
- by An, Kyung-Jin Aug 5, 2021 06:03am
- The ranitidine impurity issue gave wings to the rising prescription of proton pump inhibitors (PPIs). The share of PPI prescriptions in the antiulcer agent market grew 30% in only 2 years after the drugs containing ranitidine &8211; which used to occupy the largest share of the H2 receptor antagonists - were pulled from the market. Hanmi’s inc
- Company
- Restylane Kysse has been approved in Korea
- by jung, sae-im Aug 5, 2021 12:41am
- Galderma Korea announced on the 2nd that Hyaluronic acid filler Restylane Kysse was approved by the MFDS on July 26 for the purpose of temporarily expanding the volume of lips for adults aged 21 or older. Restylane Kysse, which received Korea's first permission for lip fillers, was developed by Galderma as Optical Balanced Technology( OBT)
- Company
- Roche’s Polivy can be prescribed at general hospitals
- by Eo, Yun-Ho Aug 5, 2021 12:40am
- The new lymphoma drug Polivy can be prescribed at general hospitals. According to related industries, ADC that combine with conventional BR therapy (Bendamustine/ Rituximab) treatments for diffuse large B-cell lymphoma (DLBCL) that have poor non-responsive prognosis of Roche. However, Polivy is still a non-reimbursed drug. Roche applied i
- Company
- Will regulations on ERP be established?
- by Aug 3, 2021 08:24pm
- Lee Nak-yeon, a presidential candidate for the Democratic Party of Korea, mentioned the need to draw up regulations on the Early Retention Program (ERP) of foreign-invested companies, including foreign pharmaceutical companies. Attention is focusing on whether frequent ERP regulations in the pharmaceutical industry will be possible. He mad
- Company
- Samsung launches Humira Biosimilar ‘Adalloce’ in Korea
- by Eo, Yun-Ho Aug 3, 2021 07:04am
- Domestic supply of the domestic biosimilar of ‘Humira’ has begun in full scale. According to industry sources, Adalloce, a biosimilar of the TNF- alpha blocker Humira(adalimumab)’s that was developed by Samsung Bioepis and sold by Yuhan Corporation in Korea, passed the Drug Committees (DCs) of 20 medical institutions including the Big
- Company
- Beijing Hanmi's 2Q operating profit increased by 50%
- by Chon, Seung-Hyun Aug 2, 2021 08:37pm
- Hanmi Pharmaceutical's second-quarter performance improved. In the domestic market, self-developed new drug products have done well. Sales of Beijing Hanmi have more than doubled despite the sluggishness caused by COVID-19. Hanmi announced on the 29th that its operating profit in the second quarter increased 49.6% year-on-year to &8361;15.9
- Company
- ACRC "Hemlibra's reimb. standards need to be reexamined"
- by Kim, Jin-Gu Aug 2, 2021 06:05am
- On the 30th, the Anti-Corruption & Civil Rights Commission (ACRC) has expressed the opinion that the reimbursement standards for the hemophilia treatment Hemlibra should be reexamined. In addition, the ACRC forwarded their official statement to the Ministry of Health and Welfare (MOHW) and the Health Insurance Review and Assessment Service (
- Company
- Daewoong recovers with record 2Q sales of ₩289.7 billi
- by An, Kyung-Jin Jul 30, 2021 05:48am
- Daewoong has continued its good performance for 2 consecutive quarters. By overcoming the heavy blows it took from the impurity issue in ranitidine and the lawsuits from its botulinum toxin strain dispute, the company was able to raise its quarterly sales to the highest level despite the COVID-19 crisis. Daewoong Pharmaceuticals has poste
